Seymour JF et al. N Engl J Med. 2018; 378(12): 1107–20.
Fischer K et al. N Engl J Med. 2019; 380: 2225–36.
Al-Sawaf O et al. EHA2021 Abstract S146. https://library.ehaweb.org/eha/2021/eha2021-virtual-congress/324554/othman.al-sawaf.venetoclax-obinutuzumab.for.previously.untreated.chronic.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dal-sawaf (accessed May 2022).
Kater AP et al. ASH 2020. Oral Abstract 125. Available from: https://ash.confex.com/ash/2020/webprogram/Paper136109.html (accessed May 2022).
You are now leaving the AbbVie Pro Portal and being re-directed to an external website which is not under the control of AbbVie. AbbVie is not responsible for content of any such site or any further links from such site.
Reporting of side effects (patients and public in the UK)
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk.
By reporting side effects you can help provide more information on the safety of this medicine.
For medicines with black triangle: ▼ means the medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects.